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Abstract: Modern lifestyle and diets have been associated with metabolic disorders and an imbalance
in the normal gut microbiota. Probiotics are widely known for their health beneﬁcial properties
targeting the gut microbial ecosystem. The aim of our study was to evaluate the preventive effect
of Lactobacillus keﬁri (L. keﬁri) administration in a fructose-rich diet (FRD) mice model. Mice were
provided with tap water or fructose-added (20% w/v) drinking water supplemented or not with
L. keﬁri. Results showed that probiotic administration prevented weight gain and epidydimal adipose
tissue (EAT) expansion, with partial reversion of the adipocyte hypertrophy developed by FRD.
Moreover, the probiotic prevented the increase of plasma triglycerides and leptin, together with the
liver triglyceride content. Leptin adipocyte secretion was also improved by L. keﬁri, being able to
respond to an insulin stimulus. Glucose intolerance was partially prevented by L. keﬁri treatment
(GTT) and local inﬂammation (TNFα; IL1β; IL6 and INFγ) was completely inhibited in EAT. L. keﬁri
supplementation generated an impact on gut microbiota composition, changing Bacteroidetes and
Firmicutes proﬁles. Overall, our results indicate that the administration of probiotics prevents the
deleterious effects of FRD intake and should therefore be promoted to improve metabolic disorders.
Keywords: gut microbiota; fructose-rich diet; adipose tissue; probiotics
1. Introduction
Obesity has been deﬁned by the World Health Organization as an Adipose Tissue (AT) excess
that could be harmful to the organism, predisposing to pathologies such as type II Diabetes Mellitus,
cardiovascular disease, dyslipidemias, fatty liver disease, and certain cancers. AT mass expansion is
associated with serious changes in AT architecture and function, among which adipocyte hypertrophy
is one of the most relevant features. Hypertrophic adipocytes are characterized by releasing
high amounts of leptin, pro-inﬂammatory cytokines, low adiponectin, and insulin-resistance [1,2].
Furthermore, AT mass expansion induces a shift from an anti- to pro-inﬂammatory proﬁle of immune
cells resident in this tissue, leading to a general pro-inﬂammatory state of AT [3,4].
Obesity is a multifactorial disorder caused by the interaction of genetic background and
environmental factors, such as altered eating habits [5]. Modern diets are characterized by high
carbohydrate intake, especially fructose-sweetened beverages, and have been associated with high
prevalence of overweight and Metabolic Syndrome (MS) in humans [6]. High-fructose feeding has
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been widely used in animal models to induce obesity and MS phenotype [7–10]. In the present study,
we used a fructose-rich diet intake (FRD, 20% w/v in drinking water), which is far from fructose intake
by humans, to generate a mice model of obesity. Previously, FRD has been related to the development
of insulin resistance, dyslipidemias, increased abdominal AT mass, and changes in the pattern of AT
adipokine secretion [7,8,11]. Partly, these metabolic disorders are a consequence of fructose-induced
hepatic de novo lipogenesis, and the resulting increase in AT fatty acid uptake [12,13].
Gut microbiota is composed of 1 to 10 trillion microorganisms, mainly bacteria, among which
approximately 90% belong to the Bacteroidetes, Firmicutes, Actinobacteria and Proteobacteria phyla [14].
Symbiotic relationships between bacteria and their hosts modulate several physiological processes
such as nutrients uptake, metabolism, and immune response, among others [15]. Environmental
factors such as diet, treatment with antibiotics, and exercise can modulate gut microbiota composition.
Obesity has been associated with gut microbiota dysbiosis, contributing to the establishment of
characteristic alterations related to obesity. Since transplantation of lean gut microbiota to obese mice
can rescue the obese phenotype [16], strategies to manipulate the composition of the gut microbiota
have gained considerable importance for metabolic pathologies management. Probiotics are deﬁned
as live microorganisms that, when administered, exert positive health effects in the host. It is largely
accepted that probiotics are involved in the maintenance of healthy gut microbiota, and for this reason
their use has emerged as a potential therapy against MS and obesity [17].
Keﬁr is a food product obtained by fermentation of milk with “keﬁr grains”. These grains
are constituted by a complex symbiotic microbiota, mainly of yeast, lactic acid, and acetic acid
bacteria conﬁned in a matrix of polysaccharides and proteins [18,19]. Several health-promoting
properties have been associated with keﬁr consumption [19,20], and the study of the beneﬁcial
properties of keﬁr-isolated microorganisms can be considered as a very important ﬁeld for the
development of functional foods. Lactobacillus keﬁri is one of the most important lactobacilli obtained
from keﬁr grains [21,22]. Different in vitro studies have revealed that secretion products and surface
proteins from different L. keﬁri strains can exert a protective action against intestinal pathogens
such as Salmonella enterica [23] and Clostridium difﬁcile [24]. Moreover, Carey and Kostrzynska
reported that L. keﬁri attenuates the pro-inﬂammatory response in intestinal epithelial cells induced by
Salmonella typhimurium, and Hong et al. showed its inﬂuence on Th1 and pro-inﬂammatory cytokine
production in macrophages [25,26].
Recent studies have demonstrated that L. keﬁri CIDCA 8348 strain resists passage through
simulated gastrointestinal conditions [27] and its oral administration is safe to mice [28]. Interestingly,
mice treated with L. keﬁri CIDCA 8348 showed a down-regulation of the gene expression of
pro-inﬂammatory mediators and an up-regulation of anti-inﬂammatory molecules, secreted IgA
and mucins in the gut [29]. Based on this evidence, we aimed to evaluate the preventive effect of
L. keﬁri CIDCA 8348 administration on the metabolic alterations caused by FRD in mice.
2. Material and Methods
2.1. Bacterial Strain and Growth Conditions
A keﬁr-isolated Lactobacillus keﬁri strain (CIDCA 8348, L. keﬁri) [30] from the collection of the
“Centro de Investigación y Desarrollo en Criotecnológico de Alimentos” (La Plata, Argentina) was
used for experiments. The strain was cultured in MRS-broth (DIFCO, Detroit, MI, USA) at 37 ◦C for
48 h under aerobic conditions. Frozen stock cultures were stored at −80 ◦C in skim milk until use.
2.2. Animals and Treatment
Normal adult male Swiss mice (four months of age, n = 15 mice per group) were kept in a
temperature-controlled environment (20–22 ◦C and ﬁxed 12 h light/12 h dark cycle, lights on at
07:00 a.m.) and fed ad libitum with Purina commercial rat chow. Mice were divided into two groups:
one was provided with tap water and the other with a 20% fructose solution (w/v, Sigma-Aldrich,
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St. Louis, MO, USA) added to tap water for 6 weeks (conventionally called fructose rich diet, FRD).
Each group was randomly divided and administered L. keﬁri (108 CFU dissolved in milk; CTR-Lk
and DRF-Lk groups) or milk alone (CTR and FRD groups) by oral gavage every 48 h during the
6-week diet. Food intake and body weight were measured every 48 h. On experimental day, mice
were euthanized under non-fasting conditions (between 08:00 a.m. and 09:00 a.m.) and trunk blood
was collected; plasma samples were then frozen (−20 ◦C) until metabolite measurements (Section 2.3).
Inguinal AT (IAT, subcutaneous depot), Epididymal AT (EAT, visceral depot) and Retroperitoneal AT
(RPAT, visceral depot) were aseptically dissected and weighed. EAT was kept in sterile Dulbecco’s
Modiﬁed Eagle’s Medium-Low Glucose (1 g/L) (DMEM-LG) for further procedures. Animals were
euthanized according to protocols for animal use, in agreement with National Institutes of Health
(NIH) guidelines for the care and use of experimental animals. All experiments were approved by our
Institutional Animal Care Committee (approval code 020916).
2.3. Peripheral Metabolite Measurements
Non-fasting plasma levels of leptin (LEP, n = 15) were determined by speciﬁc radioimmunoassays
(RIAs) previously developed in our laboratory [31]. Non-fasting plasma levels of glucose (Glu, n = 15)
and triglycerides (Tg, n = 15) were measured using commercial kits (Wiener Lab., Rosario, Argentina).
2.4. EAT Adipocyte Isolation and Incubation
Fresh EAT pads were dissected, weighed and digested with collagenase as previously
reported [32]. Brieﬂy, fat tissue was minced and digested using 1 mg/mL collagenase solution
in DMEM (at 37 ◦C, for 1 h). After centrifugation (1000 rpm for 15 min), ﬂoating mature adipocytes
were separated and diluted up to a density of approximately 200,000 cells per 900 µL DMEM-1%
BSA. Adipocytes were distributed in 24 multi-well plates and incubated for 45 min at 37 ◦C in a 5%
CO2 atmosphere with medium alone (basal) or medium containing 10 nM insulin (Novo Nordisk
Pharma AG, Küsnacht, Switzerland) [33]. After incubation, medium was carefully aspirated and kept
frozen (−20 ◦C) until measurement of LEP concentrations as described above (n = 6 independent
experiments).
2.5. EAT Pad Histology
For histological studies, freshly dissected EAT pads (n = 4 per group) were ﬁxed in 4%
paraformaldehyde, then washed with tap water, immersed in a series of graded ethanol solutions
(70%, 96% and 100%), and clariﬁed in xylene before parafﬁn embedding [34]. Four-micrometer sections
were taken from different levels of the blocks and stained with hematoxylin-eosin. Quantitative
morphometric analysis was performed using a RGB CCD Sony camera and Image Pro-Plus 4.0 software
(Image ProPlus6.0, Rockville, MD, USA). For each tissue sample, seven sections and three levels were
selected. Systematic random sampling was used to select 15 ﬁelds for each section (magniﬁcation,
×400) and 2500 cells per group were examined. Adipocyte area was measured.
2.6. Glucose Tolerance Test (GTT)
Four days before the end of the protocol, six mice from each experimental group were fasted
for 10 h (from 10:00 p.m. to 8:00 a.m.) and then glucose (2 mg/kg BW) was administered via
intraperitoneal (IP) injection. Blood was collected by the tail cut method. Glucose was measured at
0, 30, 60 and 120 min after glucose challenge by one-touch glucometer (Accu-Chek Performa, Roche,
Mannheim, Germany). Area under the curve was calculated using Graph Pad Prism 6.0 (GraphPad
Software Inc., San Diego, CA, USA).
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2.7. Liver Lipid Content
Fifty mg of the liver (n = 6 per group) was homogenized in a 5% solution of 500 µL Triton
X-100 in phosphate-buffered saline (PBS). The homogenate was incubated at 80–100 ◦C for 5 min
and centrifuged at 10,000× g for 10 min. Triglyceride (Tg) was measured in the supernatants using a
commercial kit (Wiener Lab, Rosario, Argentina).
2.8. RNA Isolation and Quantitative Real-Time PCR (qRT-PCR)
Total RNA from EAT (n = 6 per group) was isolated by the Trizol extraction method (Invitrogen,
Life Tech., Carlsbad, CA, USA) and reverse-transcribed using random primers (250 ng) and RevertAid
Reverse Transcriptase (200 U/µL, Thermo Scientiﬁc, Vilnius, Lithuania). Two µL cDNAwere ampliﬁed
with HOT FIRE Pol EvaGreenqPCR Mix Plus (Solis BioDyne, Tartu, Estonia) containing 0.5 µM of each
speciﬁc primer, using a Rotor Gene Q (Qiagen, Hilden, Germany). Polymerase chain reaction (PCR)
efﬁciency was near 1. Expression levels were analyzed for β-actin (ACTβ, reporter gene), Adiponectin
(Adipo), Leptin (Ob), Lipoprotein Lipase (LPL), Fatty Acid Synthase (FAS), Hormone Sensitive Lipase
(HSL), Adipose Triglyceride Lipase (ATGL), Tumor Necrosis Factor α (TNFα), Interleukin 1β (IL1β),
Interleukin 6 (IL6), and Interferonγ (IFNγ). Designed primers are shown in Table 1. Relative changes
in the expression level of one speciﬁc gene (∆∆Ct) were calculated by the ∆Ct method.
Table 1. Primers used for real time PCR analysis.
Gene Sequence (50-30) GBAN Size Product (bp)
ACTβ Fw: TTTGCAGCTCCTTCGTTGCCRv: ACCCATTCCCACCATCACAC NM_007393.5 189
Ob Fw: ACCAGGATCAATGACATTTCACACRv: GGCTGGTGAGGACCTGTTGA NM_008493.3 148
Adipo Fw: GGAACTTGTGCAGGTTGGATGRv: CCCTTCAGCTCCTGTCATTCC NM_009605.5 171
LPL Fw: AGGACCCCTGAAGACACRv: GGCACCCAACTCTCATA NM_008509.2 149
ATGL Fw: CCACTCACATCTACGGAGCCRv: AATCAGCAGGCAGGGTCTTC NM_001163689.1 198
HSL Fw: AGTTACCATCTCACCTCCRv: CTTGCTGTCCTGTCCTTC NM_010719.5 94
FAS Fw: CAAGCAGGCACACACAATGGRv: GCCTCGGAACCACTCACA NM_007988.3 141
TNFα Fw: CATCTTCTCAAAATTCGAGTGACAARv: CCTCCACTTGGTGGTTTGCT NM_013693.3 63
IFNγ Fw: TGGCATAGATGTGGAAGAAAAGAGRv: TGCAGGATTTTCATGTCACCAT NM_008337.4 81
IL1β Fw: CTTGTGCAAGTGTCTGAARv: AGGTCAAAGGTTTGGAAG NM_008361.4 143
IL6 Fw: GTTCTCTG GAAATCGTGGAAARv: AAGTGCATCATCGTTGTTCATACA NM_031168.2 77
Speciﬁc primers used for real time PCR analyses; Fw: Forward, Rv: Reverse; GBAN: GenBank Accession Number;
bp: base pairs.
2.9. Leptin Measurement
Medium LEP concentration was determined by speciﬁc RIA [35]. In this assay, the standard curve
ranged between 50 and 12,500 pg/mL, with intra- and inter-assay variation coefﬁcients of 4–6% and
5–8%, respectively.
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2.10. Microbiota Analysis in Feces
Fecal samples were collected at the end of the experimental protocol and were stored at −80 ◦C
prior to use for microbiota analysis. DNA extraction was performed using the AccuPrep Stool DNA
Extraction Kit (Bioneer, Daejeon, Korea) according to the manufacturer’s instructions.
2.10.1. Quantitative PCR of Microbiota Populations
Quantiﬁcation of bacterial populations was carried out using primers synthesized by Genbiotech
(Buenos Aires, Argentina). Primer sequences were previously described [ 29,36]. PCR reactions were
performed in a Rotor Gene Q (Qiagen, Hilden, Germany) using HOT FIRE Pol EvaGreenqPCR Mix
Plus (Solis BioDyne, Tartu, Estonia). Twenty ng DNA and 0.2 µmol L−1 of each primer were used in
PCR mix. A negative control reaction without template was included for each primer combination.
Melting curve was conducted from 70 ◦C to 90 ◦C, read every 0.5 ◦C during 2 s. For standard curves
we used PCR products generated from a pool of puriﬁed genomic DNA from the different samples
and the primers previously described [29,36]. Results were expressed as number of copies/g wet
weight feces.
2.10.2. Qualitative Analysis by PCR-DGGE
Primers 518r (50-ATTACCGCGGCTGCTGG-30) and 338f (50-CTCCTACGGGAGGCAGCAG-30)
coupled to a 50-GC clamp [37], targeting the V3 region of the 16S rRNA subunit [38], were used
to assess microbial diversity in each sample. PCR was performed in a Stratagene Gradient Cycler
(Agilent Technologies Inc., Philadelphia, PA, USA) using 1U of PFU DNA Polymerase (PB-L, EmbioTec
SRL, Buenos Aires, Argentina) per 50 pg of DNA template. The PCR products were separated in 8%
polyacrylamide gels (37.5:1 acrylamide:bisacrylamide) with a range of 40–60% denaturing gradient
(100% denaturant consisted of 7 M urea and 40% deionized formamide) cast in a DDGE-2401 device
(C.B.S Scientiﬁc Co., Del Mar, CA, USA). The electrophoresis was performed in TAE 0.5X buffer for
16 h at a constant voltage of 100 v and a temperature of 60 ◦C. Gels were stained with SYBR Gold
0.01 µL/mL (Invitrogen, Life Technologies, Carlsbad, CA, USA) in TAE 1X buffer and visualized in a
Bio-Rad Universal Hood II gel documentation system (Bio-Rad laboratories Inc., Hercules, CA, USA).
PyElph 1.4 software was used to calculate the dendrograms using the UPGMA (unweighted pair group
method with arithmetic mean clustering algorithm) [39].
2.11. Statistical Analysis
Results are expressed as mean values± S.E.M. Data were analyzed by ANOVA (one-way) method
followed by Fisher´s test. Body weight data were analyzed using a multivariate test (IBM SPSS statistics
22, IBM Corp., New York, NY, USA). To determine the differential effect of the treatments, ANOVA
(two-way) analysis was performed followed by Tukey’s test. p values lower than 0.05 were considered
statistically signiﬁcant. All statistical tests were performed using GraphPad Prism 6.0 (GraphPad
Software Inc., San Diego, CA, USA).
3. Results
3.1. L. keﬁri Administration Prevents Body Weight Gain and AT Expansion
Caloric intake for FRD mice was higher than that for CTR mice (Figure 1A; P < 0.05) and, as
expected, was accompanied by an increase in body weight (Figure 1B; P < 0.05 vs. CTR). L. keﬁri
administration to CTR mice (CTR-Lk group) did not modify caloric intake or body weight compared
to CTR animals. However, administration of L. keﬁri during FRD intake prevented the increase in
body weight without changing the caloric intake (P < 0.05 vs. FRD). Multivariate analysis showed
an interaction between diet and probiotic administration had a signiﬁcant effect (P = 0.02). FRD
consumption has been widely used in animal models to induce metabolic disorders as those observed
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in human MS; one of these features is the visceral AT expansion. Our results showed that FRD induced
a signiﬁcant increase in EAT mass (P < 0.05). Interestingly, probiotic treatment inhibited EAT mass
expansion induced by FRD intake (FRD-Lk mice; P < 0.05) and also decreased EAT mass in CTR-Lk
mice compared to CTR (Figure 1C; P < 0.05). With regard to other AT depots studied, although no
signiﬁcant differences were found among experimental groups, FRD mice showed a trend toward
increased IAT and RPAT mass, which was not observed in FRD-Lk mice (Figure 1D,E).
Unhealthy AT expansion has been associated with hypertrophic adipocytes while hyperplastic
AT expansion prevents AT dysfunctions. Histological analysis of adipocyte size from EAT showed
that L. keﬁri administration did not affect cell size in CTR-Lk mice (Figure 1F). On the other hand, FRD
induced an increase in adipocyte size (P < 0.01) that was not observed in FRD-Lk adipocytes. Thus,
high fructose consumption generated an unhealthy EAT expansion but was partially prevented by the
probiotic treatment.
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Figure 1. Mean of caloric intake, body weight and AT expansion. (A) Caloric intake (* P < 0.05 vs.
CTR and CTR-Lk) and (B) body weight from the different groups. (* P < 0.05 vs. CTR. + P < 0.05
vs. FRD) (C) EAT, (D) RPAT and (E) IAT mass were measured. * P < 0.05 vs. CTR and + P < 0.05 vs.
FRD. (n = 15 mice per group). (F) EAT adipocyte size. (n = 4 mice per group). ** P < 0.001 vs. CTR
and + P < 0.05 vs. FRD. (G) Representative EAT histological samples stained with hematoxylin-eosin.
Values are means ± SEM.
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3.2. Metabolic Alterations and Glucose Homeostasis Impairment Were Improved by Probiotic Treatment
FRD mice showed an impaired metabolic proﬁle, characterized by higher plasmatic concentration
of Tg and LEP than CTR mice, without changes in Glu plasmatic levels (Figure 2A–C; P < 0.05
and P < 0.01, respectively). L. keﬁri treatment did not modify these parameters in CTR-Lk mice.
Interestingly, FRD-Lk mice showed circulating levels of Tg and LEP similar to CTR mice, which reveals
the beneﬁcial effect of L. keﬁri administration on the metabolic proﬁle from high-fructose feeding mice.
Additionally, liver lipid content was similar for CTR and CTR-Lk mice (Figure 2D). As expected,
considering the strong lipogenic capacity of fructose, FRD mice showed higher liver lipid levels
(P < 0.05). This increase was in part attenuated by the administration of L. keﬁri (FRD-Lk group).
GTT was performed to assess glucose homeostasis in the different groups. Administration of
L. keﬁri to CTR mice did not modify GTT response, as shown in Figure 2E. For the case of FRD group,
we observed an impaired glucose tolerance, which was clearly evidenced in a higher area under the
curve (Figure 2F; P < 0.05). This glucose intolerance was partially prevented by L. keﬁri treatment
(FRD-Lk).
Nutrients 2017, 9, 470  7 of 17 
 
3.2. Metabolic Alterations and Glucose Homeostasis Impairment Were Improved by Probiotic Treatment 
FRD  mice  showed  an  impaired  metabolic  profile,  characterized  by  higher  plasmatic 
concentration of Tg and LEP than CTR mice, without changes in Glu plasmatic levels (Figure 2A–C; 
P < 0.05 and P < 0.01, respectively). L. kefiri treatment did not modify these parameters in CTR‐Lk 
mice. Interestingly, FRD‐Lk mice showed circulating levels of Tg and LEP similar to CTR mice, which 
reveals  the beneficial effect of L.  kefiri administration on  the metabolic profile  from high‐fructose 
feeding mice.   
Additionally, liver lipid content was similar for CTR and CTR‐Lk mice (Figure 2D). As expected, 
considering the strong lipogenic capacity of fructose, FRD mice showed higher liver lipid levels (P < 
0.05). This increase was in part attenuated by the administration of L. kefiri (FRD‐Lk group). 
GTT was performed to as ess glucose homeostasis i  t   iff rent groups. Administration of L. 
kefiri to CTR mice  id not modify G T response, as sho  i   i           f   group, 
we observed an impaired glucose tolerance, which was clearly evidenced in a hig     r t e 
curve  (Figure 2F; P < 0.05). This glucose  intolerance was partially prevente     .  fi   t 
(FRD‐Lk). 
 
Figure 2. Metabolic Parameters and Glucose Tolerance Test.  (A) Triglycerides,  (B) Leptin and  (C) 
Glucose plasma concentrations were recorded. (n = 15 mice per group). (D) Liver triglycerides content 
was assessed  in  the  four groups. Values are means ±  range  (n = 6 mice per group).  (E) GTT was 
performed four days before to the end of the protocol. Glucose concentration was measured at 0, 30, 
60 and 120 min after glucose challenge. (F) Area under the curve was calculated. Values are means ± 
SEM (n = 6 mice per group). * P < 0.05; ** P < 0.01 and *** P < 0.001 vs. CTR. + P < 0.05; ++ P < 0.01 and 
+++ P < 0.001 vs. FRD. 
E F
A
C
B
D
Figure 2. Metabolic Parameters and Glucose Tolerance Test. (A) Triglycerides, ( ( )
Glucose plasm concentrations were recorded. (n = 15 mice per group). (D) Liver tri l i t t
was assessed in the four groups. Values are means ± range (n = 6 mice per group). ( ) s
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3.3. L. keﬁri Administration Reduces EAT Dysfunctions Induced by FRD
AT dysfunction directly correlates with adipocyte size. Hypertrophic adipocytes are insulin
resistant and secrete an altered adipokyne pattern (LEP and Adipo) and pro-inﬂammatory cytokines.
As shown in Figure 3A,B, isolated EAT adipocytes from CTR-Lk secreted similar amount of LEP as
CTR mice, both spontaneously and after insulin stimulation. FRD hypertrophic adipocytes secreted
more LEP than CTR ones, and did not respond to insulin stimulus (P < 0.0001 and P < 0.0001 vs. CTR,
respectively). Under basal condition, adipocytes from FRD-Lk showed an intermediate secretion of LEP
between CTR and FRD adipocytes, suggesting a partial protection exerted by L. keﬁri administration
on the impairment of LEP secretion caused by FRD. Interestingly, when FRD-Lk adipocytes were
insulin-stimulated, they signiﬁcantly increased their LEP release (P < 0.001 vs. FRD-Lk basal),
indicating insulin sensitivity recovery (P < 0.05 vs. FRD).
When mRNA expression was analyzed, EAT from FRD expressed signiﬁcantly higher LEP levels
than CTR adipocytes (Figure 3C; P < 0.01), while L. keﬁri administration protected FRD-Lk mice from
this increase (Figure 3C; P < 0.001 vs. FRD), in agreement with results detailed above. Neither FRD
nor L. keﬁri treatment altered adiponectin mRNA levels. To assess the status of lipid metabolism in
EAT we evaluated the expression of different enzymes involved in lipolysis/lipogenesis pathway. As
shown in Figure 3D, EAT from FRD mice expressed higher mRNA levels of HSL and LPL than CTR
(HSL: P < 0.05 and LPL: P < 0.05) and CTR-Lk mice (HSL: P < 0.05 and LPL: P < 0.01), whereas Lk
administration to FRD mice prevented this increase (HSL: P < 0.05 and LPL: P < 0.01 vs. FRD).
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Fig re 3. I provement of E f ctio . (A) Leptin secretion fro cultured a ipocytes i basal
c iti s. ( ) elati e c a e of leptin secretion after insulin stimul s compared to basal secretion for
each group. (n = 6 indepe nt experiments). EAT mRNA expression of (C) LEP (Ob) and adiponectin
(Adipo) and (D) lipid metabolism-related enzymes (LPL, HSL, ATGL, FAS). (n = 6 mice per group).
Values are means ± SEM. * P < 0.05; * P < .01 and **** P < 0.0001 vs. CTR. + P < 0.05; ++ P < 0.01;
+++ P < 0.001 and ++++ P < 0.0001 vs. FRD.
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3.4. L. keﬁri Treatment Protects EAT from Inﬂammation Induced by FRD
It is well known that obesity is associatedwith AT chronic inﬂammatory state caused by the change
of AT resident immune cells from anti-inﬂammatory Type 2 to pro-inﬂammatory Type 1, favoring
insulin-resistance. In this regard, our results showed that FRD intake induced an inﬂammatory
state in EAT, evidenced by signiﬁcant increase of IL6, IL1β, TNFα and IFNγ expression (Figure 4;
P < 0.05 vs. CTR), that was prevented by L. keﬁri treatment (IFNγ: P < 0.05; IL1β: P < 0.01 and IL6:
P < 0.01 vs. FRD). Noticeably, we found that L. keﬁri administration did not modify mRNA levels of
pro-inﬂammatory cytokines in EAT from CTR-Lk mice.
Nutrients 2017, 9, 470  9 of 17 
 
It  is well known that obesity  is associated with AT chronic  inflammatory state caused by th  
change of AT reside t  immune cells  from anti‐inflammatory Type 2  to pro‐inflammatory Type 1, 
favoring  insulin‐resistance.  In  this  egard,  our  r sults  showed  that  FRD  intake  induced  an 
inflammatory stat  in EAT, eviden ed by significant increase of IL6, IL1β, T Fα and IFNγ expression 
(Figure 4; P < 0.05 vs. CTR), that was prevented by L. kefiri treatment (IFNγ: P < 0.05; IL1β: P < 0.01 
and IL6: P < 0.01 vs. FRD). Noticeably, we found that L. kefiri administration di  not modify mRNA 
levels of pro‐inflammatory cytokines in EAT from CTR‐Lk mice.   
 
Figure 4. Inflammatory profile of EAT. Gene expression of pro‐inflammatory cytokines (TNFα, INFγ, 
IL1β, IL6) in EAT from the four experimental groups. Values are means ± SEM (n = 6 mice per group). 
* P < 0.05 vs. CTR. + P < 0.05 and ++ P < 0.01 vs. FRD. 
3.5. Effects of FRD and L. kefiri Administration on Gut Microbiota Composition 
To  study  the  effects  of  diet  and  probiotic  administration  on  gut microbiota  structure, we 
analyzed the fecal bacterial composition by PCR‐DGGE and qPCR. Both FRD and Lk administration 
produced qualitative changes  in  the microbial  community  composition,  since  the  cluster analysis 
based  on  the  Pearson  product‐moment  correlation  coefficient  and  UPGMA  linkage  allowed 
differentiation of the experimental groups in separated clusters (Figure 5), without differences in the 
number of amplification bands generated from each sample (not shown). Regarding qPCR assays, 
we  performed  two‐way ANOVA  analysis  to  determine  if  FRD  or  Lk  or  the  interaction  of  both 
variables have some effect on fecal bacterial amounts. Firstly, no differences in the total number of 
bacteria  between  groups were  found,  although  a  trend  to  increase was  observed  in mice under 
probiotic  treatment,  independently  of  diet  intake  (Table  2). When  specific  bacterial  phyla were 
analyzed, we  found  a  different  effect  regarding  diet  and  probiotic  administration.  FRD  feeding 
decreased  the Lactobacillus  spp.  (Figure 6A, P = 0.015) and  increased Bacteroides  fragilis quantities 
independently of probiotic administration (Figure 6B, P = 0.0074). On the other hand, when L. kefiri 
administration was analyzed we found an increase in Firmicutes and Bacteroidetes phyla (Figure 6A, 
P = 0.007 and P = 0.027 respectively), and in Lactobacillus murinus and Bacteroides fragilis species (Figure 
6B, P = 0.0048 and P = 0.0072 respectively), in spite of mice receiving or not the FRD. No differences 
were found in L. acidophilus group when both variables were analyzed.   
TNF IFN IL-1 IL-6
0
2
4
6 CTR
FRD
CTR-Lk
FRD-Lk
+
*
*
++
*
m
R
N
A
 e
xp
re
ss
io
n 
(A
U
)  *
+
++
++
++
Figure 4. Inﬂammatory proﬁle of EAT. Gene expression of pro-inﬂammatory cytokines (TNFα, INFγ,
IL1β, IL6) in EAT from the four experimental groups. Values are means ± SEM (n = 6 mice per group).
* P < 0.05 vs. CTR. + P < 0.05 and ++ P < 0.01 vs. FRD.
3.5. Effects of F and L. keﬁri d inistration on ut icrobiota Co position
To study the effects of diet and probiotic administration on gut microbiota structure, we analyzed
the fecal bacterial composition by PCR-DGGE and qPCR. Both FRD and Lk administration produced
qualitative changes in the microbial co munity co position, since the cluster analysis based on the
Pearson product-moment correlation coefﬁcient and UPGMA linkage allowed differentiation of the
experimental groups in separated clusters (Figure 5), without differences in the number of ampliﬁcation
bands generated from each sample (not shown). Regarding qPCR assays, we performed two-way
ANOVA analysis to determine if FRD or Lk or the interaction of both variables have some effect on
fecal bacterial amounts. Firstly, no differences in the total number of bacteria between gro ps were
found, although a trend to increase was observed in mice under probiotic treatment, i depende tly
of diet intake (Table 2). When speciﬁc bacterial phyla were analyzed, we found a different effect
regarding diet and probiotic administration. FRD feeding decreased theLactobacillus spp. (Figure 6A,
P = 0.015) and increased Bacteroides fragilis quantities independently of probiotic administration
(Figure 6B, P = 0.0074). On the other hand, when L. keﬁri administration was analyzed e found an
increase in Firmicutes and Bacteroidetes phyla (Figure 6A, P = 0.007 and P = 0.027 res ectively), and in
Lactobacillus murinus and Bacteroides fragilis species (Figure 6B, P = 0.0048 and P = 0.0072 respectively),
in spite of mice receiving or not the FRD. No differences were found in L. acidophilus group when both
variables were analyzed.
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Table 2. Total bacteria quantiﬁcation in feces.
CTR CT - FRD-L
Total Bacteria (N of
copies/g of feces) 3.7 × 10
9 ± 5.6 × 108 4.97 × 109 ± 5.0 × 108 5.94 × 109 ± 6.7 × 108 6.97 × 109 ± 7.8 × 108
After the overall variable analyses, we compared the microbiota composition among the different
groups. Interestingly, we found that Bacteroidetes population from FRD-Lk mice was signiﬁcantly
increased compared to CTR (P < 0.05). Accordingly, Bacteroides fragilis (Bacteroidetes phylum) was
also increased in FRD-Lk (P < 0.05 vs. CTR and FRD) and in CTR-Lk mice (P < 0.05 vs. CTR).
Additionally, Lactobacillus murinuswas also more abundant in FRD-Lk and in CTR-Lk (P < 0.05) than
their counterparts without probiotic administration (Figure 6B). These changes in the microbiota
composition in Lk-treated mice could suggest the presence of a healthier microbiota, which could be
related to the beneﬁcial metabolic changes found in them.
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Figure 6. Analysis of microbiota composition in feces. (A) Lactobacillus spp., Lactobacillus
acidophilus (L. acidophilus) and Lactobacillus murinus (L. murinus) quantiﬁcation. (B) Firmicutes
and Bacteroidetes phyla, Clostridium coccoides group (C. coccoides group) and Bacteroides fragilis
(B. fragilis) quantiﬁcation. T o-way ANOVA was pe formed for variable analysis and Tuk y’s multiple
comparisons post-test was performed for group-to-group comparisons. ns = no signiﬁcant differences.
Values are means ± SEM (n = 3 mice per group). * P < 0.05 vs. CTR, + P < 0.05 vs. FRD.
4. Discussion
Over the few last decades, the importance of the symbiotic relationship between gut microbiota
and host in energy absorption, immune syste and metabolism has been described [ 40]. Alterations
caused by environmental factors on gut microbiota composition could lead to ho m tabolic disorders,
as has been observed in both obese humans and rodents [41–43]. Since probiotics modulate gut
microbiota and also affect host metabolism, the use of probiotics has been associated with several
metabolic improve ents in obese phenotypes [40,44]. In this regard, several studies have demonstrated
the beneﬁts of the use of lactobacill as probiotics, improving liver pathologies, among others [45,46].
Fructose-sweetened beverages are one of the most remarkable components of modern diets and
their consumption has increased notably in the last few decades [6]. Although diet is one factor that can
affect gut bacterial proﬁle in early life, as well as in adulthood, the effect of fructose on gut microbiota
has been poorly studied. In fact, the use of probiotics as a preventive tool has been addressed mostly
in high-fat diet models. FRD has been widely used to induce MS and obesity in animal models [7,8,11].
Our current results show that FRD intake for six weeks was effective in inducing an increase in
body weight and EAT mass. These changes were accompanied by higher Tg and LEP plasma levels,
peripheral insulin-resistance and increased liver lipid content, conﬁrming the deleterious effects caused
by this diet.
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In the present study, we proposed to evaluate the potential protective effect of L. keﬁri against the
metabolic disorders induced by FRD. L. keﬁri is a microorganism derived from keﬁr grains. Previous
reports have demonstrated that keﬁr improves fatty liver syndrome in ob/obmice [47] and metabolic
parameters in spontaneously hypertensive rats [48]. Interestingly, in our model the administration
of L. keﬁri completely prevented the alterations caused by FRD intake, which strongly support the
beneﬁcial effect of this probiotic. In concordance with our results, other studies have shown that the
use of Lactobacillus species as probiotics improves the metabolic disorders induced by the FRD [49,50].
There is growing evidence that AT-gut microbiota axis modulates several metabolic processes,
including adipokine secretion and lipid metabolism, among others [51]. For this reason, the
maintenance of healthier gut microbiota is relevant for the normal function of the AT. It was
demonstrated that probiotic administration to high-fat fed mice reduced the inﬁltration of
pro-inﬂammatory macrophages into AT and also adipocyte size [52]. In line with these ﬁndings,
our results showed that L. keﬁri administration to FRD-fed mice decreased the expression of several
pro-inﬂammatory cytokines in EAT, indicating a prevention of the local pro-inﬂammatory state
caused by FRD intake. Previously, it was demonstrated that orally administered L. keﬁri induces
an anti-inﬂammatory response in the gut of healthy mice [29]. This anti-inﬂammatory action could
lead to the prevention of bodyweight gain and visceral fat accumulation, as proposed as an explanation
for weight modiﬁcation induced by other lactobacilli [53]. Furthermore, the anti-inﬂammatory
effect was accompanied by a partial attenuation of adipocyte hypertrophy and an improvement of
insulin-sensitivity in FRD-Lk adipocytes. It is largely accepted that adipocyte size is directly correlated
with LEP secretion [1]. Moreover, LEP induces the secretion of pro-inﬂammatory cytokines, which in
turn have a positive feedback to LEP [43]. It has been reported that periodic administration of probiotic
mixture to obese MSG (monosodium glutamate) rats increased adiponectin levels and decreased
the leptin concentration in AT and the visceral AT mass [54]. We observed that in vitro FRD-Lk
adipocytes secreted an intermediate amount of LEP between CTR and FRD adipocytes, which was in
accordance with the partial recovery of adipocyte size in FRD-Lk and the decrease in inﬂammation.
Additionally, expression analysis in EAT from FRD mice that receivedL. keﬁri showed lower levels of
Ob, but no changes in Adipo mRNA levels compared to EAT from FRD mice. Several studies have
demonstrated the beneﬁcial effect of probiotic on lipid metabolism, by regulating the expression of
lipid metabolism-related enzymes [55–57]. Speciﬁcally, a direct effect on AT lipid metabolism has been
observed [58]. Our ﬁndings indicate that FRD intake generated an imbalance in the expression of
lipogenic/lipolitic enzymes in EAT, that was recovered by L. keﬁri administration. Overall, our results
strongly support that L. keﬁri treatment has several beneﬁcial effects in AT metabolism and function,
suggesting a tight communication between AT and the gut microbiota. However, further studies are
needed to elucidate the mechanisms involved.
Different mediators have been proposed as a link between intestinal microbiota and host
metabolism. One of these is short-chain fatty acids (SCFAs), mainly acetate, propionate and butyrate,
which are generated as a result of bacterial fermentative metabolism. Due to its heterofermentative
metabolism, L. keﬁri produces lactic acid, ethanol and carbon dioxide as main metabolites of sugar
fermentation [27]. To our knowledge, there are no scientiﬁc reports about SCFA production by L. keﬁri
strains. However, it is very interesting that Iraporda and coworkers recently demonstrated that
lactate inhibits the activation of intestinal epithelial cells triggered by different pro-inﬂammatory
stimuli [59,60]. SCFAs have been shown to generate protection against diet-induced obesity [61,62].
Several of their actions are mediated through activation of free fatty acid receptors (FFARs) [63],
some of which are abundantly expressed in AT and may be involved in regulating lipid metabolism
and glucose homeostasis [64]. Although we did not analyze the presence of lactic acid or SCFAs
in fecal samples in our study, we cannot discard the hypothesis that the production of lactate or
modiﬁcations in SCFA production may contribute to the preventive effect exerted by L. keﬁri in our
model. On the other hand, some trials suggest that another possible mechanism is a lower expression
of the tight junction proteins that generates an increased gut permeability to lipopolysaccharides
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(LPS). These bacterial ligands can stimulate immune cells, such as those from AT, thus contributing to
establish a chronic inﬂammatory state in obese individuals [41]. In fact, LPS plasma concentrations are
increased in obese individuals [65], suggesting its contribution to endotoxemia and AT inﬂammation
development during obesity.
Changes in diversity and number of bacteria in the intestinal microbiota during obesity has been
proved, however, no consensus has been reached about the composition of a healthy or unhealthy gut
microbiome [66]. In our studies, the PCR-DGGE assay showed that both FRD and Lk administration
produced qualitative changes in the microbial community composition, while no changes in diversity
were observed. Studies in animal models have shown many controversies related to Firmicutes and
Bacteroidetes abundance, depending on the diet and length of treatment (high fat, high carbohydrate
or high ﬁber diets). Some studies showed that fructose intake produces a decrease in Bacteroidetes,
while others stated no changes or even an increment [49,67]. Similarly, for Firmicutes, an increase or
no changes were reported [49,50,67]. In our study, we analyzed if both variables studied (FRD and
Lk administration) affected the microbiota composition of treated mice. Firstly, we did not ﬁnd any
changes in Firmicutes and Bacteroidetes phyla when FRD intake was analyzed. However, we did observe
a decrease in fecal Lactobacillus spp. in FRD-mice, independently if they received or not L. keﬁri. This
result agrees with those previously shown by Di Luccia et al. and Jena et al., who reported a decrease in
Lactobacillus in high fructose-fed rats [67,68]. When we evaluated the effect of L. keﬁri administration we
observed that it has a signiﬁcant positive inﬂuence in both Firmicutes and Bacteroidetes phyla, and also
in two of the four speciﬁc populations studied, B. fragilis and L. murinus. All these changes evidence an
effect per se of the L. keﬁri strain, independent from the diet, and could be suggesting the establishment
of a healthier bacterial community.
As mentioned before, most of the studies evaluating the use of probiotics have been performed in
high-fat diet models. However, some works have studied the use of probiotics in high-fructose
consumption models and its relationship with changes in microbiota composition. One report
showed an increase in both Firmicutes and Bacteroidetes quantities in small intestine when FRD
was co-administered with L. rhamnosus GG [49]. In our work, when compared group to group,
a signiﬁcant increase in Bacteroideteswas observed in FRD-Lk mice. On the other hand, Zhang et al.
reported that FRD supplemented with L. casei, increased intestinal Bacteroides fragilis (Bacteroidetes
phylum) and decreased Clostridium spp. (Firmicutes phylum) quantities, at the same time that it
improved the oral glucose tolerance test in FRD-fed rats [50]. In line with these results, FRD-fed mice
supplemented with L. keﬁri showed an increase in B. fragilis, but no changes in Clostridium coccoides
group, accompanied by an improvement of several metabolic alterations caused by FRD intake. Some
reports have described beneﬁcial effects of B. fragilis, including preventive effects against colitis and
intestinal inﬂammation [69,70], and improvement in plasma levels of triglycerides and glucose [71].
Furthermore, we found that L. murinus population was higher in FRD-Lk and CTR-Lk mice. Previously,
an increase of L. murinus in colon was associated with an improvement in the intestinal immunity [72].
Finally, when we analyzed Lactobacillus spp., we found a trend toward increase in CTR-Lk mice,
similarly to the signiﬁcant increase previously reported by our group [29]. It is worth to note that
some of these results do not completely agree with Carasi et al. (2015) [29], which could be mostly
related to the difference in the length of L. keﬁri treatment (3 weeks vs. 6 weeks). Overall, these changes
in microbiota populations may explain in part the anti-inﬂammatory and metabolic improvements
generated by L. keﬁri in Lk-treated mice. However, further studies are needed to determine the
association between changes in microbiota composition, caused by L. keﬁri administration, and the
metabolic improvements found in our model.
5. Conclusions
In summary, this work showed, as expected, that a fructose-rich diet induced endocrine-metabolic
alterations in mice that resemble those found in human MS. These alterations could be partially
caused by a dysbiosis induced by FRD; however, more studies about effects of fructose intake on
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gut microbiota are needed. In our experimental model, we evidenced that FRD does not alter the
Bacteroidetes and Firmicutes phyla, but decreases Lactobacillus spp. Moreover, we demonstrated the
beneﬁcial effects of L. keﬁri as a probiotic, such as changing gut microbiota composition and preventing
metabolic alterations and AT dysfunction induced by FRD. In this regard, we previously showed the
anti-inﬂammatory action of L. keﬁri, accordingly with a novel protective effect against AT inﬂammation.
Finally, we have contributed to reinforce the importance of probiotics as a preventive treatment for
metabolic alterations associated with obesity. In particular, the L. keﬁri strain isolated from a natural
food, such as keﬁr grains, emerges as a potential tool for obesity management.
Acknowledgments: This work was supported by grants from FONCYT (PICT-2013-0930, PICT-2015-2352 and
PICT-2012-0910). Authors are grateful to Rebecca Doyle for careful manuscript editing/correction. M.d.l.A.S., P.C.
and A.G. are researchers from the National Research Council of Argentina (CONICET).
Author Contributions: A.G., M.G.Z. and M.d.l.A.S. conceived and designed the experiments. M.G.Z. and S.E.G.
performed research. P.C. participated in qPCR assays and analyses. M.A.R. performed the histological analysis.
A.G., M.d.l.A.S., S.E.G. and M.G.Z. analyzed all data and wrote the manuscript. All the authors participated in
the critical revision and correction of the ﬁnal manuscript. All authors read and approved the ﬁnal manuscript.
Conﬂicts of Interest: The authors declare no conﬂicts of interest.
References
1. Skurk, T.; Alberti-Huber, C.; Herder, C.; Hauner, H. Relationship between adipocyte size and adipokine
expression and secretion. J. Clin. Endocrinol. Metab. 2007, 92, 1023–1033. [CrossRef] [PubMed]
2. Wåhlen, K.; Sjölin, E.; Löfgren, P. Role of fat cell size for plasma leptin in a large population based sample.
Exp. Clin. Endocrinol. Diabetes 2011, 119, 291–294. [CrossRef] [PubMed]
3. Chawla, A.; Nguyen, K.D.; Goh, Y.P.S. Macrophage-mediated inﬂammation in metabolic disease.
Nat. Rev. Immunol. 2011, 11, 738–749. [CrossRef] [PubMed]
4. Lumeng, C.N.; Bodzin, J.L.; Saltiel, A.R. Obesity induces a phenotypic switch in adipose tissue macrophage
polarization. J. Clin. Investig. 2007, 117, 175–184. [CrossRef] [PubMed]
5. Marti, A.; Martinez-González, M.A.; Martinez, J.A. Interaction between genes and lifestyle factors on obesity.
Proc. Nutr. Soc. 2008, 67, 1–8. [CrossRef] [PubMed]
6. Malik, V.S.; Popkin, B.M.; Bray, G.A.; Després, J.-P.; Willett, W.C.; Hu, F.B. Sugar-sweetened beverages
and risk of metabolic syndrome and type 2 diabetes: A meta-analysis. Diabetes Care 2010, 33, 2477–2483.
[CrossRef] [PubMed]
7. Alzamendi, A.; Zubiría, G.; Moreno, G.; Portales, A.; Spinedi, E.; Giovambattista, A. High Risk of Metabolic
and Adipose Tissue Dysfunctions in Adult Male Progeny, Due to Prenatal and Adulthood Malnutrition
Induced by Fructose Rich Diet. Nutrients 2016, 8, 178. [CrossRef] [PubMed]
8. Zubiría, M.G.; Fariña, J.P.; Moreno, G.; Gagliardino, J.J.; Spinedi, E.; Giovambattista, A. Excess fructose
intake-induced hypertrophic visceral adipose tissue results from unbalanced precursor cell adipogenic
signals. FEBS J. 2013, 280, 5864–5874. [CrossRef] [PubMed]
9. Yoo, S.; Ahn, H.; Park, Y.K. High Dietary Fructose Intake on Cardiovascular Disease Related Parameters in
Growing Rats. Nutrients 2016, 9, 11. [CrossRef] [PubMed]
10. Ciofﬁ, F.; Senese, R.; Lasala, P.; Ziello, A.; Mazzoli, A.; Crescenzo, R.; Liverini, G.; Lanni, A.; Goglia, F.;
Iossa, S. Fructose-Rich Diet Affects Mitochondrial DNA Damage and Repair in Rats. Nutrients 2017, 9, 323.
[CrossRef] [PubMed]
11. Zubiría, M.G.; Alzamendi, A.; Moreno, G.; Rey, M.A.; Spinedi, E.; Giovambattista, A. Long-Term Fructose
Intake Increases Adipogenic Potential: Evidence of Direct Effects of Fructose on Adipocyte Precursor Cells.
Nutrients 2016, 8, 198. [CrossRef] [PubMed]
12. Parks, E.J.; Skokan, L.E.; Timlin, M.T.; Dingfelder, C.S. Dietary sugars stimulate fatty acid synthesis in adults.
J. Nutr. 2008, 138, 1039–1046. [PubMed]
13. Samuel, V.T. Fructose induced lipogenesis: From sugar to fat to insulin resistance. Trends Endocrinol. Metab.
2011, 22, 60–65. [CrossRef] [PubMed]
14. Gomes, A.C.; Bueno, A.A.; de Souza, R.G.; Mota, J.F. Gut microbiota, probiotics and diabetes. Nutr. J. 2014,
13, 60. [CrossRef] [PubMed]
Nutrients 2017, 9, 470 15 of 17
15. Nieuwdorp, M.; Gilijamse, P.W.; Pai, N.; Kaplan, L.M. Role of the microbiome in energy regulation and
metabolism. Gastroenterology 2014, 146, 1525–3153. [CrossRef] [PubMed]
16. Vrieze, A.; Van Nood, E.; Holleman, F.; Salojärvi, J.; Kootte, R.S.; Bartelsman, J.F.W.M.; Dallinga-Thie, G.M.;
Ackermans, M.T.; Serlie, M.J.; Oozeer, R.; et al. Transfer of Intestinal Microbiota From Lean Donors Increases Insulin
Sensitivity in IndividualsWithMetabolic Syndrome.Gastroenterology 2012, 143, 913–916. [CrossRef] [PubMed]
17. Arora, T.; Singh, S.; Sharma, R.K. Probiotics: Interaction with gut microbiome and antiobesity potential.
Nutrition 2013, 29, 591–596. [CrossRef] [PubMed]
18. De Oliveira Leite, A.M.; Miguel, M.A.L.; Peixoto, R.S.; Rosado, A.S.; Silva, J.T.; Paschoalin, V.M.F.
Microbiological, technological and therapeutic properties of keﬁr: A natural probiotic beverage.
Braz. J. Microbiol. 2013, 44, 341–349. [CrossRef] [PubMed]
19. Bourrie, B.C.T.; Willing, B.P.; Cotter, P.D. The Microbiota and Health Promoting Characteristics of the
Fermented Beverage Keﬁr. Front. Microbiol. 2016, 7, 647. [CrossRef] [PubMed]
20. Nielsen, B.; Gürakan, G.C.; Unlü, G. Keﬁr: A multifaceted fermented dairy product. Probiotics
Antimicrob. Proteins 2014, 6, 123–135. [CrossRef] [PubMed]
21. Garrote, G.L.; Delfederico, L.; Bibiloni, R.; Abraham, A.G.; Pérez, P.F.; Semorile, L.; De Antoni, G.L.
Lactobacilli isolated from keﬁr grains: Evidence of the presence of S-layer proteins. J. Dairy Res. 2004,
71, 222–230. [CrossRef] [PubMed]
22. Hamet, M.F.; Londero, A.; Medrano, M.; Vercammen, E.; Van Hoorde, K.; Garrote, G.L.; Huys, G.;
Vandamme, P.; Abraham, A.G. Application of culture-dependent and culture-independent methods for the
identiﬁcation of Lactobacillus keﬁranofaciens in microbial consortia present in keﬁr grains. Food Microbiol. 2013,
36, 327–334. [CrossRef] [PubMed]
23. Golowczyc, M.A.; Mobili, P.; Garrote, G.L.; Abraham, A.G.; De Antoni, G.L. Protective action of Lactobacillus
keﬁr carrying S-layer protein against Salmonella enterica serovar Enteritidis. Int. J. Food Microbiol. 2007, 118,
264–273. [CrossRef] [PubMed]
24. Carasi, P.; Trejo, F.M.; Pérez, P.F.; De Antoni, G.L.; Serradell, M.A. Surface proteins from Lactobacillus kefir
antagonize in vitro cytotoxic effect of Clostridium difficile toxins. Anaerobe 2012, 18, 135–142. [CrossRef] [PubMed]
25. Carey, C.M.; Kostrzynska, M. Lactic acid bacteria and biﬁdobacteria attenuate the proinﬂammatory response
in intestinal epithelial cells induced by Salmonella enterica serovar Typhimurium. Can. J. Microbiol. 2013, 59,
9–17. [CrossRef] [PubMed]
26. Hong, W.S.; Chen, H.C.; Chen, Y.P.; Chen, M.J. Effects of keﬁr supernatant and lactic acid bacteria isolated
from keﬁr grain on cytokine production by macrophage. Int. Dairy J. 2009, 19, 244–251. [CrossRef]
27. Carasi, P. Potencialidad Probiótica de Lactobacilos con Capa S. Estudios sobre la inocuidad, efecto
antimicrobiano y capacidad inmunomodulatoria de Lactobacillus keﬁri. Ph.D. Thesis, United Nations
Laissez-Passer (UNLP), La Plata, Argentina, 2014.
28. Carasi, P.; Díaz, M.; Racedo, S.M.; De Antoni, G.; Urdaci, M.C.; Serradell, M.A. Safety Characterization and
Antimicrobial Properties of Keﬁr-Isolated Lactobacillus keﬁri. BioMed Res. Int. 2014, 2014, 208974. [CrossRef]
[PubMed]
29. Carasi, P.; Racedo, S.M.; Jacquot, C.; Romanin, D.E.; Serradell, M.A.; Urdaci, M.C. Impact of keﬁr derived
Lactobacillus keﬁri on the mucosal immune response and gut microbiota. J. Immunol. Res. 2015, 2015, 361604.
[CrossRef] [PubMed]
30. Garrote, G.L.; Abraham, A.G.; De Antoni, G.L. Chemical and microbiological characterisation of keﬁr grains.
J. Dairy Res. 2001, 68, 639–652. [CrossRef] [PubMed]
31. Perelló, M.; Gaillard, R.C.; Chisari, A.; Spinedi, E. Adrenal enucleation in MSG-damaged hyperleptinemic
male rats transiently restores adrenal sensitivity to leptin. Neuroendocrinology 2003, 78, 176–184. [CrossRef]
[PubMed]
32. Giovambattista, A.; Gaillard, R.C.; Spinedi, E. Ghrelin gene-related peptides modulate rat white adiposity.
Vitam. Horm. 2008, 77, 171–205. [PubMed]
33. Alzamendi, A.; Giovambattista, A.; García, M.E.; Rebolledo, O.R.; Gagliardino, J.J.; Spinedi, E. Effect of
pioglitazone on the fructose-induced abdominal adipose tissue dysfunction. PPAR Res. 2012, 2012, 259093.
[CrossRef] [PubMed]
34. Alzamendi, A.; Castrogiovanni, D.; Gaillard, R.C.; Spinedi, E.; Giovambattista, A. Increased male offspring’s
risk of metabolic-neuroendocrine dysfunction and overweight after fructose-rich diet intake by the lactating
mother. Endocrinology 2010, 151, 4214–4223. [CrossRef] [PubMed]
Nutrients 2017, 9, 470 16 of 17
35. Giovambattista, A.; Piermaría, J.; Suescun, M.O.; Calandra, R.S.; Gaillard, R.C.; Spinedi, E. Direct effect of
ghrelin on leptin production by cultured rat white adipocytes. Obesity 2006, 14, 19–27. [CrossRef] [PubMed]
36. Malinen, E.; Kassinen, A.; Rinttilä, T.; Palva, A. Comparison of real-time PCR with SYBR Green I or
50-nuclease assays and dot-blot hybridization with rDNA-targeted oligonucleotide probes in quantiﬁcation
of selected faecal bacteria. Microbiology 2003, 149, 269–277. [CrossRef] [PubMed]
37. Muyzer, G.; de Waal, E.C.; Uitterlinden, A.G. Proﬁling of complex microbial populations by denaturing
gradient gel electrophoresis analysis of polymerase chain reaction-ampliﬁed genes coding for 16S rRNA.
Appl. Environ. Microbiol. 1993, 59, 695–700. [PubMed]
38. Cocolin, L.; Alessandria, V.; Botta, C.; Gorra, R.; De Filippis, F.; Ercolini, D.; Rantsiou, K. NaOH-debittering
induces changes in bacterial ecology during table olives fermentation. PLoS ONE 2013, 8, e69074. [CrossRef]
[PubMed]
39. Pavel, A.B.; Vasile, C.I. PyElph—A software tool for gel images analysis and phylogenetics.BMC Bioinform.
2012, 13, 9. [CrossRef] [PubMed]
40. Cani, P.D.; Delzenne, N.M. The role of the gut microbiota in energy metabolism and metabolic disease.
Curr. Pharm. Des. 2009, 15, 1546–1558. [CrossRef] [PubMed]
41. Drissi, F.; Raoult, D.; Merhej, V. Metabolic role of lactobacilli in weight modiﬁcation in humans and animals.
Microb. Pathog. 2016. [CrossRef] [PubMed]
42. Tilg, H.; Kaser, A. Gut microbiome, obesity, and metabolic dysfunction. J. Clin. Investig. 2011, 121, 2126–2132.
[CrossRef] [PubMed]
43. Harper, J.W.; Zisman, T.L. Interaction of obesity and inﬂammatory bowel disease. World J. Gastroenterol. 2016,
22, 7868. [CrossRef] [PubMed]
44. Vieira, L.Q.; dos Santos, L.M.; Neumann, E.; da Silva, A.P.; Moura, L.N.; Nicoli, J.R. Probiotics Protect Mice
Against Experimental Infections. J. Clin. Gastroenterol. 2008, 42, S168–S169. [CrossRef] [PubMed]
45. Lebeer, S.; Vanderleyden, J.; De Keersmaecker, S.C.J. Genes and molecules of lactobacilli supporting probiotic
action. Microbiol. Mol. Biol. Rev. 2008, 72, 728–764. [CrossRef] [PubMed]
46. Xu, R.-Y.; Wan, Y.-P.; Fang, Q.-Y.; Lu, W.; Cai, W. Supplementation with probiotics modiﬁes gut ﬂora and
attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J. Clin. Biochem. Nutr. 2012,
50, 72–77. [CrossRef] [PubMed]
47. Chen, H.-L.; Tung, Y.-T.; Tsai, C.-L.; Lai, C.-W.; Lai, Z.-L.; Tsai, H.-C.; Lin, Y.-L.; Wang, C.-H.; Chen, C.-M.
Keﬁr improves fatty liver syndrome by inhibiting the lipogenesis pathway in leptin-deﬁcient ob/ob knockout
mice. Int. J. Obes. 2014, 38, 1172–1179. [CrossRef] [PubMed]
48. Rosa, D.D.; Grzes´kowiak, Ł.M.; Ferreira, C.L.L.F.; Fonseca, A.C.M.; Reis, S.A.; Dias, M.M.; Siqueira, N.P.;
Silva, L.L.; Neves, C.A.; Oliveira, L.L.; et al. Keﬁr reduces insulin resistance and inﬂammatory cytokine
expression in an animal model of metabolic syndrome. Food Funct. 2016, 7, 3390–3401. [CrossRef] [PubMed]
49. Ritze, Y.; Bárdos, G.; Claus, A.; Ehrmann, V.; Bergheim, I.; Schwiertz, A.; Bischoff, S.C. Lactobacillus rhamnosus
GG protects against non-alcoholic fatty liver disease in mice. PLoS ONE 2014, 9, e80169. [CrossRef] [PubMed]
50. Zhang, Y.; Wang, L.; Zhang, J.; Li, Y.; He, Q.; Li, H.; Guo, X.; Guo, J.; Zhang, H. Probiotic Lactobacillus casei
Zhang ameliorates high-fructose-induced impaired glucose tolerance in hyperinsulinemia rats.Eur. J. Nutr.
2014, 53, 221–232. [CrossRef] [PubMed]
51. Machado, M.; Cortez-Pinto, H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int. J. Mol. Sci.
2016, 17, 481. [CrossRef] [PubMed]
52. Wang, J.; Tang, H.; Zhang, C.; Zhao, Y.; Derrien, M.; Rocher, E.; van-Hylckama Vlieg, J.E.; Strissel, K.; Zhao, L.;
Obin, M.; et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome
in high fat diet-fed mice. ISME J. 2015, 9, 1–15. [CrossRef] [PubMed]
53. Miyoshi, M.; Ogawa, A.; Higurashi, S.; Kadooka, Y. Anti-obesity effect of Lactobacillus gasseri SBT2055
accompanied by inhibition of pro-inﬂammatory gene expression in the visceral adipose tissue in diet-induced
obese mice. Eur. J. Nutr. 2014, 53, 599–606. [CrossRef] [PubMed]
54. Savcheniuk, O.A.; Virchenko, O.V.; Falalyeyeva, T.M.; Beregova, T.V.; Babenko, L.P.; Lazarenko, L.M.;
Demchenko, O.M.; Bubnov, R.V.; Spivak, M.Y. The efﬁcacy of probiotics for monosodium glutamate-induced
obesity: Dietology concerns and opportunities for prevention. EPMA J. 2014, 5, 2. [CrossRef] [PubMed]
55. Kim, B.; Park, K.-Y.; Ji, Y.; Park, S.; Holzapfel, W.; Hyun, C.-K. Protective effects of Lactobacillus rhamnosus GG
against dyslipidemia in high-fat diet-induced obese mice. Biochem. Biophys. Res. Commun. 2016, 473, 530–536.
[CrossRef] [PubMed]
Nutrients 2017, 9, 470 17 of 17
56. Wang, Y.; Xu, N.; Xi, A.; Ahmed, Z.; Zhang, B.; Bai, X. Effects of Lactobacillus plantarum MA2 isolated
from Tibet keﬁr on lipid metabolism and intestinal microﬂora of rats fed on high-cholesterol diet.
Appl. Microbiol. Biotechnol. 2009, 84, 341–347. [CrossRef] [PubMed]
57. Kawase, M.; Hashimoto, H.; Hosoda, M.; Morita, H.; Hosono, A. Effect of administration of fermented
milk containing whey protein concentrate to rats and healthy men on serum lipids and blood pressure.
J. Dairy Sci. 2000, 83, 255–263. [CrossRef]
58. Cui, C.; Shen, C.J.; Jia, G.; Wang, K.N. Effect of dietary Bacillus subtilis on proportion of Bacteroidetes
and Firmicutes in swine intestine and lipid metabolism. Genet. Mol. Res. 2013, 12, 1766–1776. [CrossRef]
[PubMed]
59. Iraporda, C.; Romanin, D.E.; Rumbo, M.; Garrote, G.L.; Abraham, A.G. The role of lactate on the
immunomodulatory properties of the nonbacterial fraction of keﬁr. Food Res. Int. 2014, 62, 247–253.
[CrossRef]
60. Iraporda, C.; Errea, A.; Romanin, D.E.; Cayet, D.; Pereyra, E.; Pignataro, O.; Sirard, J.C.; Garrote, G.L.;
Abraham, A.G.; Rumbo, M. Lactate and short chain fatty acids produced by microbial fermentation
downregulate proinﬂammatory responses in intestinal epithelial cells and myeloid cells. Immunobiology 2015,
220, 1161–1169. [CrossRef] [PubMed]
61. Gao, Z.; Yin, J.; Zhang, J.; Ward, R.E.; Martin, R.J.; Lefevre, M.; Cefalu, W.T.; Ye, J. Butyrate Improves Insulin
Sensitivity and Increases Energy Expenditure in Mice. Diabetes 2009, 58, 1509–1517. [CrossRef] [PubMed]
62. Lin, H.V.; Frassetto, A.; Kowalik, E.J.; Nawrocki, A.R.; Lu, M.M.; Kosinski, J.R.; Hubert, J.A.; Szeto, D.; Yao, X.;
Forrest, G.; et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones
via free fatty acid receptor 3-independent mechanisms. PLoS ONE 2012, 7, e35240. [CrossRef] [PubMed]
63. Ichimura, A.; Hasegawa, S.; Kasubuchi, M.; Kimura, I. Free fatty acid receptors as therapeutic targets for the
treatment of diabetes. Front. Pharmacol. 2014, 5, 236. [CrossRef] [PubMed]
64. Kimura, I.; Ozawa, K.; Inoue, D.; Imamura, T.; Kimura, K.; Maeda, T.; Terasawa, K.; Kashihara, D.; Hirano, K.;
Tani, T.; et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid
receptor GPR43. Nat. Commun. 2013, 4, 1829. [CrossRef] [PubMed]
65. Boutagy, N.E.; McMillan, R.P.; Frisard, M.I.; Hulver, M.W. Metabolic endotoxemia with obesity: Is it real and
is it relevant? Biochimie 2016, 124, 11–20. [CrossRef] [PubMed]
66. Payne, A.N.; Chassard, C.; Lacroix, C. Gut microbial adaptation to dietary consumption of fructose, artiﬁcial
sweeteners and sugar alcohols: Implications for host-microbe interactions contributing to obesity. Obes. Rev.
2012, 13, 799–809. [CrossRef] [PubMed]
67. Di Luccia, B.; Crescenzo, R.; Mazzoli, A.; Cigliano, L.; Venditti, P.; Walser, J.-C.; Widmer, A.; Baccigalupi, L.;
Ricca, E.; Iossa, S. Rescue of Fructose-Induced Metabolic Syndrome by Antibiotics or Faecal Transplantation
in a Rat Model of Obesity. PLoS ONE 2015, 10, e0134893. [CrossRef] [PubMed]
68. Jena, P.K.; Singh, S.; Prajapati, B.; Nareshkumar, G.; Mehta, T.; Seshadri, S. Impact of targeted speciﬁc
antibiotic delivery for gut microbiota modulation on high-fructose-fed rats. Appl. Biochem. Biotechnol. 2014,
172, 3810–3826. [CrossRef] [PubMed]
69. Mazmanian, S.K.; Round, J.L.; Kasper, D.L. A microbial symbiosis factor prevents intestinal inﬂammatory
disease. Nature 2008, 453, 620–625. [CrossRef] [PubMed]
70. Mazmanian, S.K.; Liu, C.H.; Tzianabos, A.O.; Kasper, D.L. An immunomodulatory molecule of symbiotic
bacteria directs maturation of the host immune system. Cell 2005, 122, 107–118. [CrossRef] [PubMed]
71. Haro, C.; Garcia-Carpintero, S.; Alcala-Diaz, J.F.; Gomez-Delgado, F.; Delgado-Lista, J.; Perez-Martinez, P.;
Rangel Zuñiga, O.A.; Quintana-Navarro, G.M.; Landa, B.B.; Clemente, J.C.; et al. The gut microbial
community in metabolic syndrome patients is modiﬁed by diet. J. Nutr. Biochem. 2016, 27, 27–31. [CrossRef]
[PubMed]
72. Tang, C.; Kamiya, T.; Liu, Y.; Kadoki, M.; Kakuta, S.; Oshima, K.; Hattori, M.; Takeshita, K.; Kanai, T.; Saijo, S.;
et al. Inhibition of Dectin-1 Signaling Ameliorates Colitis by Inducing Lactobacillus-Mediated Regulatory T
Cell Expansion in the Intestine. Cell Host Microbe 2015, 18, 183–197. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
